Drugs in MeSH Category Progestins

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	CRINONE	progesterone	GEL;VAGINAL	020701-002	Jul 31, 1997		RX	Yes	Yes
Acertis Pharms	PROMETRIUM	progesterone	CAPSULE;ORAL	019781-001	May 14, 1998	AB	RX	Yes	No
Xiromed	PROGESTERONE	progesterone	INSERT;VAGINAL	218391-001	Sep 19, 2025	AB	RX	No	No
Dr Reddys	PROGESTERONE	progesterone	CAPSULE;ORAL	208801-002	Feb 28, 2017	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Progestins

Last updated: December 17, 2025

Summary

The progestins class, encompassing synthetic progestogens used primarily in contraception, hormone therapy, and reproductive health, demonstrates significant market growth driven by demographic shifts, evolving medical guidelines, and technological advancements. The patent landscape reveals a competitive environment characterized by patent expirations, biosimilar entry, and ongoing innovation targeting improved efficacy, safety, and novel delivery systems. This report critically analyzes the current market environment, patent strategies, and future outlook for progestin-based drugs, guided by recent data, regulatory policies, and key IP filings.

Introduction to Progestins

Progestins (or progestogens) are synthetic compounds mimicking the hormone progesterone, integral to contraceptive applications, hormone replacement therapy (HRT), and treatment of menstrual disorders. The National Library of Medicine’s MeSH classification situates Progestins under hormonal agents affecting the reproductive system, reflecting their broad therapeutic utility.

Types of Progestins

Category	Example Drugs	Mode of Action	Common Uses
First-generation	Norethisterone, Medroxyprogesterone	Inhibition of ovulation, endometrial stabilization	Contraception, HRT
Second-generation	Levonorgestrel	Potent progestogenic activity, rapid action	Emergency contraception, contraceptive implants
Third-generation	Desogestrel	Reduced androgenic activity	Oral contraception
Fourth-generation	Drospirenone	Anti-mineralocorticoid effects	Contraception, acne treatment

Market Dynamics: Current Landscape and Trends

Global Market Size and Projections

Metric	2022 Estimate	2027 Projection	CAGR (2023–2027)	Key Drivers
Market Valuation	USD 4.5 billion	USD 6.8 billion	9.2%	Rising demand for hormonal contraceptives, aging populations, expanding HRT markets
Regional Distribution	North America (40%), Europe (25%), Asia-Pacific (25%), Rest of World (10%)	Same as above		Favorable reimbursement policies, technological advancements

Demand Drivers

• Demographic Shifts: Rising women’s health consciousness, increasing menopause management, and adolescent contraception needs.
• Regulatory Environment: Supportive policies for contraceptive access, approval of new formulations.
• Technological Innovation: Long-acting reversible contraception (LARC), microsphere/implant delivery systems.
• COVID-19 Impact: Accelerated telemedicine adoption and disrupted supply chains, with some delays in new product launches.

Market Challenges

• Patent Expirations: Leading brands face significant patent cliffs, allowing biosimilar competition.
• Safety Concerns: Risks linked to thromboembolic events with certain formulations impact market approval.
• Pricing Pressures: Regulatory pricing controls in key markets limit revenue growth.
• Biosimilar Competition: Entry of biosimilars and generics diminishes market exclusivity.

Patent Landscape

Patent Filing and Expiry Trends

Patent Category	Number of Active Patents (2023)	Expiry Timeline	Notable Patent Holders
Composition of Matter	150	2024-2035	Bayer, Teva, Pfizer, Merck
Delivery System (LAR, implants)	70	2025-2037	Allergan, Bayer, Mimedx
Crystalline Formulations	50	2023-2030	Gedeon Richter, Mersana
Novel Derivatives	60	2024-2038	Bayer, Eisai, HRA Pharma

Key Patent Strategies

• Evergreening: Filing secondary patents on formulations, delivery systems, and polymorphs to extend exclusivity.
• Combination Patents: Combining progestins with estrogens, antibiotics, or other molecules for branded products.
• Innovative Delivery: Focused on sustained-release systems, biodegradable implants, and transdermal patches.
• Geographical Expansion: Filing for patent protection in emerging markets with high fertility rates.

Biosimilars and Generics

• Several brands are approaching patent expiry, with biosimilar entrants already in some markets (e.g., Liraglutide biosimilars for certain hormonal therapies).
• Notably, Levonorgestrel patents expired in multiple jurisdictions by 2017–2020, accelerating generic entry.

Key Patent Holders & Past Patent Expiries

Patent Holder	Notable Patents	Expiry Year	Market Impact
Bayer	Norethisterone, Drospirenone	2023–2029	Loss of market exclusivity, generic competition
Pfizer	Medroxyprogesterone	2025	Increased biosimilar activity
Teva	Levonorgestrel	2018–2022	U.S. generics, market destabilization
Gedeon Richter	Crystalline forms	2024–2030	Patent-protected formulations

Innovation Focus in Patents

• Long-acting formulations: Implants (e.g., Nexplanon), injections (e.g., Depo-Provera).
• Transdermal patches: Improving compliance and steady hormone release.
• Biodegradable implants: Enhancing safety and reducing removal procedures.
• Selective modulators: Developing compounds with improved safety profiles, e.g., drospirenone derivatives.

Regulatory and Policy Environment

• FDA and EMA Guidance: Emphasis on biosimilar development, patent linkage, and clinical validation (latest guidances updated 2022–2023).
• Patent Regulations: Data exclusivity periods (e.g., 5 years in the US) impacting biosimilar entry timing.
• Global Access Policies: WHO recommendations supporting affordable family planning options influence market expansion strategies.

Comparative Analysis: Progestins versus Competing Hormonal Agents

Aspect	Progestins	Estrogens	Selective Estrogen Receptor Modulators (SERMs)
Primary Use	Contraception, HRT, menstrual disorders	Contraception, HRT	Breast cancer, osteoporosis
Patent Expiry Trends	Multiple patents near expiry (2018–2025)	Older patents mostly expired	Ongoing development, some patents live
Market Growth Potential	High, driven by new formulations	Maturation phase	Niche but innovative applications

Future Outlook

The progestin market is expected to grow at a CAGR of ~9% through 2027, fueled by innovation in delivery systems, new indications, and expanding markets in Asia-Pacific. Patent expiries present both challenges (biosimilar competition) and opportunities (strategic patenting, licensing). Development of next-generation compounds with improved safety and tolerability will likely sustain innovation momentum.

---

Key Takeaways

• Patent expiries in 2023–2025 have opened the floodgates for biosimilars and generics, intensifying competition but also creating licensing opportunities.
• Innovations center around long-acting formulations and advanced delivery systems, aiming for improved compliance and patient outcomes.
• Emerging markets in Asia-Pacific will drive volume growth, supported by favorable regulatory environments and unmet needs.
• Intellectual property strategies emphasize secondary patents, combination formulations, and novel delivery mechanisms.
• Regulatory policies are increasingly harmonized toward biosimilar acceptance, reducing market entry barriers.

---

FAQs

1. What are the primary patent expiration dates impacting the progestin market?
Most key patents for leading brands, such as norethisterone and levonorgestrel, are expiring between 2023 and 2025, paving the way for biosimilars and generics.

2. How does innovation in delivery systems influence patent strategies?
Long-acting and biodegradable delivery systems are protected via separate patents, enabling companies to extend market exclusivity even after the primary compound patents expire.

3. Are biosimilars posing a significant threat to innovator drugs in the progestin class?
Yes. Especially in markets like Europe and Asia, biosimilar entry for formulations like depot injections and implants is increasing, impacting pricing and market share.

4. Which regions present the most promising growth opportunities?
Asia-Pacific, with a CAGR of over 10%, offers promising growth due to increasing contraception needs and expanding healthcare coverage.

5. How do regulatory frameworks affect patent and market strategies?
Stringent patent linkage and data exclusivity policies in key markets like the US and EU incentivize innovative patent filings and strategic partnerships, whereas evolving policies in developing countries expand access.

---

References

1. National Library of Medicine. MeSH Database. Progestins. 2022.
2. MarketsandMarkets. "Hormonal Contraceptives Market by Product, Application, and Region," 2022.
3. U.S. Food and Drug Administration. Guidance for Industry. Biosimilars. 2022.
4. European Medicines Agency. Reflection Paper on Long-Acting Reversible Contraceptives. 2023.
5. PatentScope. World Intellectual Property Organization. Patent filings and expiries related to progestins, 2018–2023.